Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance

Penumbra Inc

2024-Q1 EPS reported $0.28 revenue$278,655,000

Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.
GAAP operating income $12.1M vs $8.0M YoY; non-GAAP operating income $19.3M.
Adjusted EBITDA $37.6M (13.5% margin); cash & investments rose $24.3M sequentially.
FY2024 guidance reaffirmed: total revenue growth 16-20%, U.S. thrombectomy growth 27-30%.
Gross margin improved to 65.0% from 62.6% on favorable product mix and productivity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the first fiscal quarter ended March 31, 2024 results: revenue $278.7 million. Guidance reaffirmed.

Period: the first fiscal quarter ended March 31, 2024
Revenue: $278.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. • Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency 1 , compared to the first quarter of 2023. • U.S. thrombectomy revenue of $150.3 million in the

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-24-000058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.